DiaMedica Therapeutics (NASDAQ:DMAC) Stock Price Down 1.5% – Here’s What Happened

Shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) dropped 1.5% on Tuesday . The company traded as low as $6.52 and last traded at $6.64. Approximately 206,697 shares traded hands during mid-day trading, a decline of 0% from the average daily volume of 207,556 shares. The stock had previously closed at $6.74.

Analysts Set New Price Targets

A number of research firms recently commented on DMAC. Wall Street Zen raised DiaMedica Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Friday, July 17th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $12.00.

DiaMedica Therapeutics Stock Down 1.5%

The company has a market capitalization of $357.76 million, a price-to-earnings ratio of -9.35 and a beta of 0.97. The business’s 50-day moving average is $6.51 and its 200-day moving average is $7.04.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.02). As a group, analysts expect that DiaMedica Therapeutics, Inc. will post -0.86 EPS for the current year.

Institutional Trading of DiaMedica Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Members Wealth LLC acquired a new position in DiaMedica Therapeutics in the fourth quarter valued at approximately $864,000. Truvestments Capital LLC grew its stake in shares of DiaMedica Therapeutics by 112.3% during the 4th quarter. Truvestments Capital LLC now owns 9,849 shares of the company’s stock worth $78,000 after purchasing an additional 5,210 shares during the period. BNP Paribas Financial Markets grew its stake in shares of DiaMedica Therapeutics by 24.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 18,882 shares of the company’s stock worth $74,000 after purchasing an additional 3,709 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of DiaMedica Therapeutics during the 2nd quarter valued at approximately $56,000. Finally, JPMorgan Chase & Co. purchased a new position in shares of DiaMedica Therapeutics during the 2nd quarter valued at approximately $49,000. 10.12% of the stock is owned by institutional investors and hedge funds.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical?stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein?kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.